VISIA Imaging is proud to say that Bio-Rad Laboratories
has entered into an agreement that gives it commercialization
rights to VISIA Imaging's second-generation immunofluorescence
slide processing and reading platform for the evaluation
of autoimmune diseases.
Bio-Rad to commercialize VISIA Imaging's
immunofluorescence slide technology
VISIA's second-generation system integrates automated slide processing with reading of immunofluorescence slides, and Bio-Rad noted that the platform will be used to automatically process slides, capture images, and aid in the interpretation of immunofluorescence results.
"We are excited about the opportunity to partner with VISIA Imaging", said John Hertia, Bio-Rad Executive Vice President and President, Clinical Diagnostics. "The platform offers a standardized and automated workflow that is needed by laboratories to handle their ever increasing IFA workloads."
"We are delighted to work with Bio-Rad Laboratories for the commercialization of this platform into new global markets", said Alessandro Foggi, CEO of VISIA Imaging. "As the worldwide prevalence of autoimmune disease continues to grow, laboratories will benefit from this automated digital platform that includes slide processing, image acquisition, analysis, and archiving."
For more information, please refer to the following link at Bio-Rad website.